quinagolide and Parkinson-Disease--Secondary

quinagolide has been researched along with Parkinson-Disease--Secondary* in 1 studies

Other Studies

1 other study(ies) available for quinagolide and Parkinson-Disease--Secondary

Article	Year
Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1990, Volume: 5, Issue:3 Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205-502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L-DOPA. CV 205-502, which combines structural features common to both ergolines and apomorphine, thus revealed interesting antiparkinsonian properties, but nausea and vomiting were dose-limiting side effects in all patients tested. Topics: Administration, Oral; Aged; Aminoquinolines; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Receptors, Dopamine	1990

Article

Year

Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society, 1990, Volume: 5, Issue:3

Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205-502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L-DOPA. CV 205-502, which combines structural features common to both ergolines and apomorphine, thus revealed interesting antiparkinsonian properties, but nausea and vomiting were dose-limiting side effects in all patients tested.

Topics: Administration, Oral; Aged; Aminoquinolines; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Receptors, Dopamine

1990